Please provide your email address to receive an email when new articles are posted on . The FDA issued a warning in 2019 about serious breathing problems associated with gabapentinoids. The study ...

Gabapentinoid use in patients with chronic obstructive pulmonary disease (COPD) was associated with a higher risk for severe exacerbations, a population-based cohort study from Canada indicated. Among ...

Patients with both chronic obstructive pulmonary disease (COPD) and severe pain are at an almost 40% predicted probability of falling, indicating the potential interaction between the conditions.

Compared with placebo, the time to first moderate or severe exacerbation was longer with mepolizumab. HealthDay News — For patients with chronic obstructive pulmonary disease (COPD) with a history of ...

Severe COPD exacerbations are pivotal for both respiratory decline and cardiovascular vulnerability, with increased medication use post-exacerbation. Cardiovascular events occurred in 18.5% of ...

In some patients with chronic obstructive pulmonary disease (COPD), type 2 inflammation may increase exacerbation risk and may be indicated by elevated blood eosinophil counts. Dupilumab, a fully ...

Please provide your email address to receive an email when new articles are posted on . Patients receiving dupilumab vs. placebo had a significantly lower risk for at least one severe exacerbation.

Enanta’s portfolio of RSV replication inhibitors with potential for first-in-disease and best-in-disease treatment.

The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease (COPD), Sanofi and Regeneron announced on Friday. An injectable interleukin ...

Sanofi and Regeneron’s Dupixent appears set up for a key FDA approval this summer for chronic obstructive pulmonary disorder (COPD). But a second biologic treatment could be on its heels in the ...